Chuck Moon, a congestive heart failure patient, experienced significant improvement in his quality of life after receiving a Barostim device implant. The Barostim device is a new technology that acts ...
CMS proposed to retain Barostim implant procedure in APC 1580 with a $45,000 outpatient payment, enhancing reimbursement for heart failure treatments. CVRx, Inc. announced that the Centers for ...
Minneapolis medical device maker CVRx Inc. is one step closer to putting to market what it says is the world’s first heart failure neuromodulation device. On Friday, the company announced that it has ...
CVRx, Inc. announced at the Technology and Heart Failure Therapeutics (THT) conference that new real-world evidence demonstrates significant reductions in hospital visits and length of stay after ...
CVRx Inc's has recovered towards previous highs following the fallout of its BeAT-HF trial results in February 2023. Adoption and utilization of its Barostim product have continued to accelerate. The ...
Heavy selloff following top-line data from the BeAT-HF trial, that failed to meet primary endpoint. Still, there were numerous secondary data that were positive. CVRX is subsequently submitting for ...
CHINA GROVE — A single heartbeat can mean the difference between life and death. Even for how vital it is, your heart can still be taken for granted every single day it works, until suddenly it fails.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback